The MAFEIP tool is a flexible web-based monitoring framework designed to assess the impact of a large variety of interventions in the health and care sector relative to current care. Interventions are understood as any application of organized knowledge, skills and resources in the form of medicines, medical devices, vaccines, procedures and systems developed to solve a health problem and improve quality of life. Some examples of interventions include the application of new care pathways, development of new devices that predict and avoid negative effects, innovative new surgical techniques and procedures, and others.
The MAFEIP tool is based on an analytical decision model, specifically a traditional Markov model with three health states, that allows to be adapted to different types of interventions and makes it possible to estimate the health and economic outcomes that result from implementing such interventions with respect to standard care. As a result, the overall impact of the intervention is shown using a cost-effectiveness plane, where the Incremental Cost Effectiveness Ratio (ICER) of the intervention under assessment is displayed. The figure below shows the cost-effectiveness plane interpretation.
Therefore, MAFEIP represents a clear support to the decision-making process based on existing knowledge and practice, existing concepts, and existing indicators starting from EUROSTAT concepts.
Why used MAFEIP?
To support your own decision-making process
MAFEIP can be used by a variety of stakeholders in different types of innovation:
- The 3-state Markov model provides the flexibility required to be adaptable to different interventions, which focus on a variety of objectives and target different cohorts of individuals with different demographic or disease characteristics.
- When data is scarce and scattered, MAFEIP allows synthesis of the best information currently available from multiple sources.
To save time and resources for decision-making
MAFEIP can be used by a variety of stakeholders in different stages of the innovation:
- MAFEIP allows performing an early assessment and the resulting evidence can help to make informed decisions about the future design of the technology or decision, at an early stage during the product life cycle (“decision to invest”). It can be used with limited resources, especially when building-up large scale trials is difficult for you and/or not feasible within short deadline.
- At a later stage of the innovation development, MAFEIP can help to assess with better precision the value of the innovation for citizens and other stakeholders (“decision to buy”).
To ensure a clear understanding of the MAFEIP tool, adequate support materials are provided in the Support Section. A Users’ Guide and the Data Collection Codebook are some examples of supporting documents.
The first version of the MAFEIP tool was developed by the Joint Research Centre – IPTS – of the EU Commission in close cooperation with the Commission's services and EIP on AHA partners. Documents providing the conceptual description of MAFEIP and the underlying basis of the tool are available hereunder.